Advertisement

Advance Class of Antibiotics of the Twenty-First Century

  • Sadhana Sagar
  • Shilpa Kaistha
  • Amar Jyoti Das
  • Rajesh Kumar
Chapter

Abstract

Microbes are the dominating organism on earth; they have impacted the life of animals as well as on humans during the course of evolution. Humans have encounter with plethora of microbes in several ways. Consequently, microbes get familiarized themselves with a new host (human) and further shared their residence with the most complex and intelligent organism on earth. The desire of humans for a civilized life them on a battlefield. Herein, the complex and brainy organisms were defeated by tiny creatures many times. During this phase microbes acquired several traits which helped them in conquering the battle with humans, and adversely affacted thier life. After the incorporation of techniques, micrbial world could explored. Sophisticated instruments have revealed fine aspects of microbes and get familiarized that they as bad as good. There are sever epidemic and pandemics have been reported those threateded the humanity.  Ancient medical history is an evidence of deadly pathogens and failure of controlling strategies. However, the modern era of antibiotic brought some hope for disease-free civilized life on this planet. In this chapter, the details of twenty-first-century antibiotics have been discussed.

References

  1. Abraham EP, Chain E (1940) An enzyme from bacteria able to destroy penicillin. Nature 146(3713):837CrossRefGoogle Scholar
  2. Burnet M, Burnet FM, White DO (1972) Natural history of infectious disease. CUP ArchiveGoogle Scholar
  3. Cullinan M, Clarke M, Dallman T, Peart S, Wilson D, Weiand D (2017) Salmonella Typhimurium gastroenteritis leading to chronic prosthetic vascular graft infection. JMM Case Rep 4(8):e005104CrossRefGoogle Scholar
  4. Dawson R, Harris K, Conradie A, Burger D, Murray S, Mendel C, Spigelman M (2017) Efficacy of bedaquiline, pretomanid, moxifloxacin & PZA (BPAMZ) against DS-& MDR-TB. In: Conference on retroviruses and opportunistic infections [proceedings on the internet], pp 13–16Google Scholar
  5. Donadio S, Maffioli S, Monciardini P, Sosio M, Jabes D (2010) Antibiotic discovery in the twenty-first century: current trends and future perspectives. J Antibiot 63(8):423CrossRefGoogle Scholar
  6. Eckburg P (2009) Focus 1 and 2: randomized double-blinded, multicenter phase III trials of the efficacy and safety of ceftaroline (CPT) vs ceftriaxone (CRO) in community-acquired pneumonia (CAP). In: Abstracts of papers of 49th Intersci Conf on Antimicrob Agents Chemother, San Francisco, 2009Google Scholar
  7. European Centre for Disease Prevention and Control (2008) Annual epidemiological report on communicable diseases, 2008. European Centre for Disease Prevention of Control, StockholmGoogle Scholar
  8. FDA, DRAFT GUIDANCE (2017 January) Medical product communications that are consistent with the Food and Drug Administration-required Labeling—questions and answers, https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm537130.pdf
  9. Fernandes P, Martens E, Bertrand D, Pereira D (2016) The solithromycin journey—it is all in the chemistry. Bioorg Med Chem.  https://doi.org/10.1016/j.bmc.2016.08.035
  10. Garcia-Salguero C, Rodriguez-Avial I, Picazo JJ, Culebras E (2015) Can plazomicin alone or in combination be a therapeutic option against carbapenem-resistant Acinetobacter baumannii? Antimicrob Agents Chemother 59(10). (2015)):5959–5966CrossRefGoogle Scholar
  11. Gibbons RJ (1964) The source of salivary bacteria. Arch Oral Biol 9:101–103CrossRefGoogle Scholar
  12. Gonzalez-Escobedo G, Marshall JM, Gunn JS (2011) Chronic and acute infection of the gall bladder by Salmonella Typhi: understanding the carrier state. Nat Rev Microbiol 9(1):9CrossRefGoogle Scholar
  13. Gottlieb S, Food, U.S (2018) Statement from FDA Commissioner Scott Gottlieb. In: MD on new steps to improve FDA review of shared risk evaluation and mitigation strategies to improve generic drug access. US Food and Drug Administration. [Online]. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm584259.htm. p 14
  14. Hunter PR (2003) Climate change and waterborne and vector-borne disease. J Appl Microbiol 94:37–46CrossRefGoogle Scholar
  15. Kepplinger EE (2015) FDA’s expedited approval mechanisms for new drug products. Biotechnol Law Rep 34(1):15–37CrossRefGoogle Scholar
  16. Kirby WM (1944) Extraction of a highly potent penicillin inactivator from penicillin resistant staphylococci. Science 99(2579):452–453CrossRefGoogle Scholar
  17. Lapuebla A, Abdallah M, Olafisoye O, Cortes C, Urban C, Landman D, Quale J (2015) Activity of imipenem with relebactam against gram-negative pathogens from New York City. Antimicrob Agents Chemother 59(8):5029–5031.  https://doi.org/10.1128/AAC.00830-15CrossRefPubMedPubMedCentralGoogle Scholar
  18. Low M (2017) The tuberculosis treatment pipeline: a breakthrough year for the treatment of XDR-TB. PIPELINE REPORT. p 129Google Scholar
  19. Mack A, Choffnes ER, Hamburg MA, Relman DA (eds) (2009) Microbial evolution and co-adaptation: a tribute to the life and scientific legacies of Joshua Lederberg: workshop summary. National Academies PressGoogle Scholar
  20. Nelson K et al (2017) Whole-genome sequencing and spatial analysis of XDR-TB transmission in South Africa. Conference on Retroviruses and Opportunistic Infections (CROI 2017), Seattle, abstract 77Google Scholar
  21. Noel GJ, Bush K, Bagchi P, Ianus J, Strauss RS (2008) A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis 46(5):647–655CrossRefGoogle Scholar
  22. O’Gara JP (2017) Into the storm: chasing the opportunistic pathogen Staphylococcus aureus from skin colonisation to life-threatening infections. Environ Microbiol 19(10):3823–3833CrossRefGoogle Scholar
  23. Patz JA, Graczyk TK, Geller N, Vittor AY (2000) Effects of environmental change on emerging parasitic diseases. Int J Parasitol 30(12–13):1395–1405CrossRefGoogle Scholar
  24. Ryan F (1992) The forgotten plague: how the battle against tuberculosis was won – and lost. Little, Brown, p 323Google Scholar
  25. Saxton K, Baines SD, Freeman J, O’Connor R, Wilcox MH (2009) Effects of exposure of Clostridium difficile PCR ribotypes 027 and 001 to fluoroquinolones in a human gut model. Antimicrob Agents Chemother 53(2):412–420CrossRefGoogle Scholar
  26. Sparling PF (1983a) Bacterial virulence and pathogenesis: an overview. Rev Infect Dis 5(Suppl 4):S637–S646CrossRefGoogle Scholar
  27. Sparling GP (1983b) Estimation of microbial biomass and activity in soil using microcalorimetry. J Soil Sci 34(2):381–390Google Scholar
  28. Surber J (2009) Efficacy and safety of torezolid phosphate (torezolid) in a dose-ranging phase 2 randomized, double-blind study in patients with severe complicated skin and skin structure infections (cSSSI). In: Abstracts of papers of 49th Interscience Conference on Antimicrob Agents Chemother, San Francisco, 2009Google Scholar
  29. Tenover FC, McGowan JE Jr (1996) Reasons for the emergence of antibiotic resistance. Am J Med Sci 311(1):9–16CrossRefGoogle Scholar
  30. Tiberi S, Payen MC, Manika K, Ladeira I, Gonzalez Sanz M, Muñoz-Torrico M et al (2018) Clinical cases. In: Migliori GB, Bothamley G, Duarte R (eds) Tuberculosis (ERS monograph). European Respiratory Society, Sheffield, pp 381–398Google Scholar
  31. Wilson ME (1995) Travel and the emergence of infectious diseases. Emerg Infect Dis 1(2):39CrossRefGoogle Scholar
  32. Ylikoski J, Savolainen S, Jousimies-Somer H (1989) Bacterial flora in the nasopharynx and nasal cavity of healthy young men. ORL 51(1):50–55CrossRefGoogle Scholar
  33. Zhanel GG, Cheung D, Adam H, Zelenitsky S, Golden A, Schweizer F, Gorityala B, Lagace-Wiens PR, Walkty A, Gin AS, Hoban DJ, Karlowsky JA (2016) Review of eravacycline, a novel fluorocycline antibacterial agent. Drugs 76(5):567–588CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Sadhana Sagar
    • 1
  • Shilpa Kaistha
    • 2
  • Amar Jyoti Das
    • 3
  • Rajesh Kumar
    • 3
  1. 1.Department of MicrobiologyRani Lakshmi Bai Central Agricultural UniversityJhansiIndia
  2. 2.Department of MicrobiologyChhatrapati Sahu Ji Maharaj UniversityKanpurIndia
  3. 3.Department of Environmental MicrobiologyBabasaheb Bhimrao Ambedkar UniversityLucknowIndia

Personalised recommendations